Skip to content

The efficacy and safety of pre-operative sublingual misoprostol versus post-operative sublingual misoprostol, as adjunct to oxytocin in reducing blood loss at caesarean section in women at risk of primary postpartum haemorrhage: a triple-blind randomized control.

The efficacy and safety of pre-operative sublingual misoprostol versus post-operative sublingual misoprostol, as adjunct to oxytocin in reducing blood loss at caesarean section in women at risk of primary postpartum haemorrhage: a triple-blind randomized control.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
PACTR
Registry ID
PACTR202503660614467
Enrollment
122
Registered
2025-03-19
Start date
2025-03-18
Completion date
Unknown
Last updated
2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pregnancy and Childbirth

Interventions

postoperative sublingual misoprostol

Sponsors

Ebolum Daniel Eziafa
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: maternal anaemia(Hb < 9.9 g%) multiple gestation chronic maternal medical disorders( cardiac,renal,DM) pre-eclampsia and gestational hypertension peripartum haemorrhage accidental haemorrhage placenta previa previous history of uterine atony or PPH polyhydramnios fetal macrosomia high parity(grand multiparity) prolonged labor/obstructed labor abruptio placenta induction of labour with oxytocin in first stage of labour augmentation of labour functinal or anatomic distortion of the uterus by submucous or intramural fibroid consenting parturients

Exclusion criteria

Exclusion criteria: non-consenting parturients patients with known bleeding disorders history of allergic reactions to prostaglandins preterm deliveries abnormaly invasive placenta 3 or more previous CS scar intra-uterine fetal death unconscious patients

Design outcomes

Primary

MeasureTime frame
the primary outcome will be estimated intra-operative blood loss, peri-operative fall in packed cell volume and maternal pyrexia.

Secondary

MeasureTime frame
nausea and vomiting, headaches, shivering

Countries

Nigeria

Contacts

Public ContactDaniel Ebolum

Principal investigator and Public enquiries

danebolum@gmail.com+2438034788816

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Feb 4, 2026